<?xml version='1.0' encoding='utf-8'?>
<document id="30284597"><sentence text="Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies." /><sentence text="ACT-541468 is a novel dual orexin receptor antagonist (DORA) under development for the treatment of insomnia" /><sentence text=" In vitro studies suggested a significant role of CYP3A4 in ACT-541468 metabolism and an impact on CYP3A4 activity" /><sentence text="" /><sentence text="Subsequently, two clinical cross-over studies investigated the victim (n = 14 healthy subjects) and perpetrator (n = 20) potential of 25 mg ACT-541468 with respect to CYP3A4" /><sentence text=" The effect of food intake on the pharmacokinetics of ACT-541468 was also investigated"><entity charOffset="54-64" id="DDI-PubMed.30284597.s6.e0" text="ACT-541468" /></sentence><sentence text="" /><sentence text="Moderate CYP3A4 inhibition by diltiazem (240 mg/day) increased the Cmax and AUC0-∞ of ACT-541468 by 1" /><sentence text="4-fold (90% confidence interval (CI): 1" /><sentence text="2-1" /><sentence text="6) and 2" /><sentence text="4-fold (90% CI: 2" /><sentence text="0-2" /><sentence text="8), respectively, and prolonged t½ by 80% (90% CI: 60-90) without affecting tmax" /><sentence text=" Single- and multiple-dose administration of 25 mg ACT-541468 had no impact on the pharmacokinetics of the sensitive substrate midazolam and its main metabolite 1-hydroxy midazolam indicated by 90% CI of the geometric mean ratios of Cmax and AUC within bioequivalence criteria and by an unchanged tmax"><entity charOffset="51-61" id="DDI-PubMed.30284597.s15.e0" text="ACT-541468" /><entity charOffset="127-136" id="DDI-PubMed.30284597.s15.e1" text="midazolam" /><entity charOffset="161-180" id="DDI-PubMed.30284597.s15.e2" text="1-hydroxy midazolam" /><pair ddi="false" e1="DDI-PubMed.30284597.s15.e0" e2="DDI-PubMed.30284597.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30284597.s15.e0" e2="DDI-PubMed.30284597.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30284597.s15.e0" e2="DDI-PubMed.30284597.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30284597.s15.e1" e2="DDI-PubMed.30284597.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30284597.s15.e1" e2="DDI-PubMed.30284597.s15.e2" /></sentence><sentence text=" After a high-fat high-calorie breakfast, the pharmacokinetic profile of 25 mg ACT-541468 showed a decrease of Cmax by 24% (90% CI: 17-31) and a delay of tmax by approximately 2 h (90% CI: 1" /><sentence text="4-2" /><sentence text="4), whereas t½ and AUC0-24 remained essentially unchanged" /><sentence text=" ACT-541468 given alone or in combination with diltiazem, midazolam, or food was safe and well tolerated"><entity charOffset="58-67" id="DDI-PubMed.30284597.s19.e0" text="midazolam" /></sentence><sentence text="" /><sentence text="Overall, ACT-541468 has been determined as CYP3A4 substrate but without any perpetrator drug-drug interaction potential regarding CYP3A4 in humans"><entity charOffset="9-19" id="DDI-PubMed.30284597.s21.e0" text="ACT-541468" /></sentence><sentence text=" Food affected ACT-541468 absorption without modifying overall exposure"><entity charOffset="15-25" id="DDI-PubMed.30284597.s22.e0" text="ACT-541468" /></sentence><sentence text="" /></document>